Accurately assess and monitor airway inflammation.
While airway inflammation is known to be the major underlying characteristic of asthma, there are few methods of measuring it. Evaluating airway inflammation using induced sputum or airway biopsy is considered the gold standard however it is expensive, invasive, time-consuming, and often not readily available. The majority of patients with asthma have Type 2/Th2 allergic/eosinophilic driven airway inflammation and higher levels of nitric oxide (NO) in their exhaled breath.4 By mesuring the concentration of NO in an exhaled breath (fractional exhaled nitric oxide or FeNO), clinicians can evaluate airway inflammation in patients with asthma.
NIOX VERO® is a non-invasive, simple and safe, and time-saving FeNO device which offers:
•Accurate FeNO results in a single measurement at the point of care5
•FeNO results in approximately ONE minute
•Routine FeNO monitoring to aid in treatment optimization
•The ability to evaluate an asthma patient’s response to anti-inflammatory therapy
To date, over 18 million tests have been performed using a NIOX device, supporting clinicians to enhance the accuracy of diagnosis and better-personalized control
Established in 1984, MMSI represents manufacturers from Canada, United States, England and Europe. Through our four business units: Hospital Specialty Products, Medical Supply Dealers, Home Health Care and Retail Pharmacies we are proud to offer innovative, cost effective and high quality products, prompt service and informed advice.